Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
Data Resource Profile: The Cancer Public Library Database in South Korea.
Choi DW, Guk M, Kim H, Ryu KS, Kong HJ, Cha HS, Kim HJ, Chae H, Jeon YS, Kim H, Jung J, Im JS, Choi KS. Choi DW, et al. Among authors: im js. Cancer Res Treat. 2024 Apr 30. doi: 10.4143/crt.2024.207. Online ahead of print. Cancer Res Treat. 2024. PMID: 38697846 Free article.
The CPLD is a unique resource for diverse cancer research to investigate medical use before a cancer diagnosis, during initial diagnosis and treatment, and long-term follow-up. This offers expanded insight into healthcare delivery across the cancer continuum, from screenin …
The CPLD is a unique resource for diverse cancer research to investigate medical use before a cancer diagnosis, during initial diagnosis and …
Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies.
Saengboon S, Ciurea SO, Popat UR, Ramdial JL, Bashir Q, Alousi AM, Chen J, Rondon G, Olson AL, Im JS, Hosing C, Shpall EJ, Champlin RE, Srour SA. Saengboon S, et al. Among authors: im js. Blood Adv. 2024 Mar 23:bloodadvances.2023010625. doi: 10.1182/bloodadvances.2023010625. Online ahead of print. Blood Adv. 2024. PMID: 38607399
Long-term survivors were defined as patients who were alive and disease free at 2 years after transplant. ...Late relapses were rare, and age was the only predictive factor for long-term outcomes....
Long-term survivors were defined as patients who were alive and disease free at 2 years after transplant. ...Late relapses were rare, …
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021.
Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, Kim JE, Kong HJ, Im JS, Seo HG; Community of Population-Based Regional Cancer Registries. Park EH, et al. Among authors: im js. Cancer Res Treat. 2024 Apr;56(2):357-371. doi: 10.4143/crt.2024.253. Epub 2024 Mar 13. Cancer Res Treat. 2024. PMID: 38487832 Free PMC article.
Survival rates have improved over the years, leading to a growing population of cancer survivors, necessitating a comprehensive cancer control strategy. The long-term impact of the pandemic on cancer statistics requires future investigation....
Survival rates have improved over the years, leading to a growing population of cancer survivors, necessitating a comprehensive cancer contr …
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Khouri IF, et al. Among authors: im js. Am J Hematol. 2024 May;99(5):836-843. doi: 10.1002/ajh.27254. Epub 2024 Feb 23. Am J Hematol. 2024. PMID: 38400519 Clinical Trial.
Here we report on the first prospective study evaluating the safety and long-term survival when an escalating dose of inotuzumab ozogamicin (INO) (0.6, 1.2, or 1.8 mg/m(2) on day 13) was added to one alkylator-containing conditioning regimen in patients with relapsed CD22 …
Here we report on the first prospective study evaluating the safety and long-term survival when an escalating dose of inotuzumab ozog …
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020.
Kang MJ, Jung KW, Bang SH, Choi SH, Park EH, Yun EH, Kim HJ, Kong HJ, Im JS, Seo HG; Community of Population-Based Regional Cancer Registries*. Kang MJ, et al. Among authors: im js. Cancer Res Treat. 2023 Apr;55(2):385-399. doi: 10.4143/crt.2023.447. Cancer Res Treat. 2023. PMID: 36915245 Free PMC article.
As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in …
As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects …
Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial.
Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Mehta RS, et al. Among authors: im js. Transplant Cell Ther. 2021 Nov;27(11):913.e1-913.e12. doi: 10.1016/j.jtct.2021.07.021. Epub 2021 Jul 28. Transplant Cell Ther. 2021. PMID: 34329753 Free article. Clinical Trial.
The objective was to evaluate NRM, relapse, survival, the rates of graft-versus-host disease (GVHD), and long-term complications. The median age of the patient population was 61 years (interquartile range, 55-67). ...
The objective was to evaluate NRM, relapse, survival, the rates of graft-versus-host disease (GVHD), and long-term complications. The …
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.
Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Mehta RS, et al. Among authors: im js. Haematologica. 2019 Dec;104(12):e555-e557. doi: 10.3324/haematol.2018.214429. Epub 2019 Apr 4. Haematologica. 2019. PMID: 30948491 Free PMC article. Clinical Trial. No abstract available.
Does hypertension increase mortality risk from lung cancer? A prospective cohort study on smoking, hypertension and lung cancer risk among Korean men.
Lee SY, Kim MT, Jee SH, Im JS. Lee SY, et al. Among authors: im js. J Hypertens. 2002 Apr;20(4):617-22. doi: 10.1097/00004872-200204000-00017. J Hypertens. 2002. PMID: 11910295
However, after stratification for smoking status, the risk ratio was increased only for current smokers (RR 1.4, 95% CI 1.2-1.6). When the interaction term was included in the multivariate model, there was a significant interactive effect of hypertension with current smoki …
However, after stratification for smoking status, the risk ratio was increased only for current smokers (RR 1.4, 95% CI 1.2-1.6). When the i …